AAPS 2022 PharmSci 360

��ɫAV

Start

Sunday, October 16, 2022 - 09:00

End

Wednesday, October 19, 2022 - 17:00

Location: Boston, United States

Booth Number: 1043

AAPS 2022 - Schedule a meeting with ��ɫAV in Boston, USA | HOVIONE CDMO The integrated specialist

Visit ��ɫAV’s booth at��next October 16-19 in Boston and meet our team of experts.

��

��ɫAV´s pragmatic approach to bridging science with manufacturing is now being leveraged for��continuous tableting.

Continuous tableting is suited for all type of��drug products for oral delivery, including the production of precision medicines and breakthrough therapies. This technology assures robust supply of quality product through enhanced process control strategies while using the same equipment for development and commercial-scale production.

��

��ɫAV presentation with Luis Sobral at AAPS

HOVIONE PRESENTATION

On October 17th, don't miss our presentation: “Accelerate Manufacturing Processes Development with Computational Chemistry” with Luís Sobral, Fellow Scientist.

10:00 AM - 10:30 AM ET

��

Poster Sessions

Monday, October 17, 2022 | 2:30 PM – 3:30 PM ET
Poster: Use of PAT Tools in the Development, Monitor and Control of Continuous Manufacturing Processes
Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, ��ɫAV

Tuesday, October 18, 2022 | 9:30 AM – 10:30 AM ET
Poster: Enhancing the “Right First Time” Concept in Continuous Manufacturing–Development Strategy
Presenting Author: Ricardo Sousa, MS - Senior Formulation Development Scientist, ��ɫAV

Tuesday, October 18, 2022 | 11:30 AM – 12:30 PM ET
Poster: Recent Advances in ASD Formulations: HIPROS and Dispersome
Presenting Author: Inês Ramos, PhD - Formulation Scientist, ��ɫAV
��

��

Let’s discuss your project together.

��

Lisbon, Portugal – ��ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ��ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ��ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ��ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ��ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ��ɫAV’s sustainability ambitions. ��ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating. Learn more about Science Based-Targets

News

��ɫAV commitment to setting SBTs in line with the Paris Agreement

��ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

��ɫAV

Browser not supported

Press Room